Izotropic Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IZO.CN research report →
Companyizocorp.com
Izotropic Corporation, a MedTech company, commercializes diagnostic products for breast cancer. It develops and commercializes breast CT Imaging system; and 3D CT breast imaging platform for the earlier detection and diagnosis of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.
- CEO
- Robert Louis Thast
- IPO
- 2018
- HQ
- Surrey, BC, CA
Price Chart
Valuation
- Market Cap
- $16.90M
- P/E
- -6.40
- P/S
- 0.00
- P/B
- -3.02
- EV/EBITDA
- -8.31
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 48.20%
- ROIC
- 113.44%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-3,139,710 · -101.09%
- EPS
- $-0.05 · -84.48%
- Op Income
- $-2,102,838
- FCF YoY
- -7.38%
Performance & Tape
- 52W High
- $0.49
- 52W Low
- $0.19
- 50D MA
- $0.26
- 200D MA
- $0.30
- Beta
- 2.34
- Avg Volume
- 28.57K
Get TickerSpark's AI analysis on IZO.CN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IZO.CN Coverage
We haven't published any research on IZO.CN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IZO.CN Report →